Biopharmaceutical Excipients Market Size to Surpass USD 6.16 BN by 2032
The global biopharmaceutical excipients market size was estimated at USD 3.6 billion in 2022 and is expected to surpass around USD 6.16 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 5.51% during the forecast period 2023 to 2032.
Key Takeaways:
Biopharmaceutical Excipients Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 3.8 Billion |
| Market Size by 2032 | USD 6.16 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 5.51% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Merck KGaA; Colorcon; BASF SE; Associated British Foods plc; Signet Excipients Pvt. Ltd (IMCD); Sigachi Industries Limited; Spectrum Chemical Manufacturing Corp.; Roquette Frères; IMCD; Clariant; DFE Pharma; J. RETTENMAIER & SÖHNE GmbH + Co KG; Evonik Industries AG |
The increasing focus of pharmaceutical players on the generic market, rising adoption of multifunctional excipients, and patent expiry of biological actives are the key factors propelling market growth. Furthermore, the cost-efficiency & competency of manufacturers and the chemical and physical instability of biopharmaceuticals are boosting the development of excipients, thus propelling the market.
The demand for biosimilars has increased in recent years, which has in turn led to a rise in the demand for biopharmaceutical excipients. Supporting factors such as patent expirations, increasing government funding, patient demographics, and rising affordability have propelled the adoption of biosimilars across the globe. In addition, the rapidly evolving healthcare infrastructure in developing economies has increased their use in the production of biogenerics. Furthermore, the introduction of well-framed legislation to ensure proper regulatory and testing standards for biosimilars globally is set to ease market entry for manufacturers.
Moreover, the growing acceptance of multi-functional biopharmaceutical excipients in industries is also driving market growth. They are efficient and effective in enhancing the manufacturing process for biopharmaceuticals. Associated advantages include better product quality, improved productivity, and reduced operating costs. The success of COVID-19 vaccines majorly relies on their efficiency, which has been enhanced by using efficient drug delivery systems; this offers immense lucrative opportunities for market entities.
Key operating players in the market are focusing on the development and launch of novel biopharmaceutical excipients. For instance, in April 2021, DFE Pharma introduced a new excipient product line ‘BioHale’ to address global supply challenges for biopharmaceutical companies. Furthermore, the geographical expansion of manufacturing facilities is increasing, owing to the rising demand for biopharmaceutical excipients. For instance, in May 2022, DFE Pharma opened a new facility in India to offer fast-track formulation services, including excipients, for pharmaceutical players to achieve the right formulations.
However, issues pertaining to the supply chain in the biopharmaceutical industry and challenges in the development of excipients for biologics are expected to hamper the market during the forecast period. Selecting the right excipient for biopharmaceuticals is a challenging and complicated task, as an excipient effective in one formulation may cause degradation or aggregation of the protein in another. A limited number of known & approved products for the stabilization of protein further increases challenges for biopharma manufacturers. Hence, to deal with these challenges, researchers are developing new and innovative approaches. For instance, to maintain the stability of lipid-based excipients (HMC excipients), researchers have applied polyglycerol esters of fatty acids (PGFAs). Currently, these products are witnessing an increasing demand for the development of COVID-19 vaccines.
Product Insights
Carbohydrate-based excipient products dominated the market in 2022 with a revenue share of 35.91%, and this trend is expected to continue through the forecast period. The extensive use of starch, sucrose, and dextrose in various drug formulations can be primarily attributed to the dominant share of the segment.
High-purity carbohydrates such as trehalose are being rapidly adopted in the development of biosimilars due to their ability to enhance the yield of the final product, stabilize various biologics, prevent aggregation, and improve the entire process of biopharmaceutical manufacturing. In addition, the increasing adoption of carbohydrates as bulking agents for assisting in the process of lyophilization for biomolecules such as proteins is further contributing to segment growth.
The polyols segment is expected to witness the fastest CAGR over the forecast period. Polyols are sugar alcohols found in certain fruits, vegetables, and sugar-free sweeteners. The growth of this segment can be attributed to the increasing demand for protein therapeutics. Polyols are added in protein formulations for increasing tonicity and stability. Moreover, they have also been shown to offer greater thermodynamic stability, which is essential for protein-based formulations.
Most therapies based on biomolecules are lyophilized to prevent aggregation and degradation. All lyophilized formulations use one or the other polyol. Sorbitol (polysorbate 80 & polysorbate 20) and mannitol are the most widely used polyols. In October 2022, Roquette introduced two next-generation mannitol excipients, PEARLITOL 200 GT and PEARLITOL CR-H, for direct compression and controlled release of mini tabs and tablets.
Regional Insights
North America accounted for the largest market share of 31.95% in 2022. The regional growth can be attributed to several large-scale pharmaceutical manufacturing companies operating in this region. The region has witnessed a significant demand for biopharmaceutical production, along with the need to maintain the quality of high-grade raw materials used to develop biopharmaceuticals. This has compelled several regional excipient manufacturers to achieve the required production scalability by using biopharmaceutical excipients that comply with the regulatory standards.
Furthermore, companies operating in the region are conducting new studies for developing efficient excipient solutions. For instance, in February 2021, Innophos released a whitepaper that focused on co-processed multifunctional excipients for enhancing compressibility, increasing manufacturing efficiency, simplifying labels, and reducing tablet size. This technology will continue to grow as it helps in reducing ingredients on the label without compromising efficacy and will help in reducing operational costs for manufacturers.
The Asia Pacific market is anticipated to witness the fastest growth rate of around 6.1% during the projection period, owing to the presence of large CMOs involved in drug development. Countries in this region such as South Korea, India, and China are majorly involved in the advancement of biosimilars. There are numerous reasons for the extensive development of biosimilars, including the presence of a large patient pool, cost advantages, affordability, and favorable regulatory framework.
Numerous biopharmaceutical manufacturers, who are potential customers for the market, have their manufacturing units in Asian countries. International biopharma players are involved in shifting their manufacturing and R&D operation sites to these countries owing to the significant cost advantages offered in the value chain. The spiraling demand for biosimilars is, in turn, bolstering the demand for novel excipients. These factors are expected to propel the Asia Pacific region’s growth in the near future.
Some of the prominent players in the Biopharmaceutical Excipients Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Biopharmaceutical Excipients market.
By Product
By Region
Chapter 1 Biopharmaceutical Excipients Market: Research Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Definitions
1.1.1.1 Product Segment
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Nova one advisor Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2 Biopharmaceutical Excipients Market: Executive Summary
2.1 Market Outlook
2.2 Product Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Biopharmaceutical Excipients Market: Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Related/Ancillary Market Outlook
3.2 Market Dynamics
3.2.1 Market Drivers Analysis
3.2.1.1 Chemical And Physical Instability Of Biopharmaceuticals Is Boosting The Development Of Excipients
3.2.1.2 Increase In Focus Of Pharmaceutical Players On Biogeneric Market
3.2.1.3 Cost Effective And Competency Of Manufacturers
3.2.1.4 Patent Expiry Of Biological Actives
3.2.1.5 Rising Adoption Of Multifunctional Excipients
3.2.2 Market Restraint Analysis
3.2.2.1 Challenges In Development Of Excipients For Biologics
3.2.2.2 Issues Pertaining To Supply Chain In Biopharmaceutical Industry
3.3 Industry Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Pestel Analysis
Chapter 4 Biopharmaceutical Excipients Market: Product Business Analysis
4.1 Biopharmaceutical Excipients Market: Product Movement Analysis
4.2 Solubilizes & Surfactants/Emulsifiers
4.2.1 Solubilizes & Surfactants/Emulsifiers Market Estimates And Forecast, 2020 - 2032
4.2.2 Triglycerides
4.2.2.1 Triglycerides Market Estimates And Forecast, 2020 - 2032
4.2.3 Esters
4.2.3.1 Esters Market Estimates And Forecast, 2020 - 2032
4.2.4 Others
4.2.4.1 Others Market Estimates And Forecast, 2020 - 2032
4.3 Polyols
4.3.1 Polyols Market Estimates And Forecast, 2020 - 2032
4.3.2 Mannitol
4.3.2.1 Mannitol Market Estimates And Forecast, 2020 - 2032
4.3.3 Sorbitol
4.3.3.1 Sorbitol Market Estimates And Forecast, 2020 - 2032
4.3.4 Others
4.3.4.1 Others Market Estimates And Forecast, 2020 - 2032
4.4 Carbohydrates
4.4.1 Carbohydrates Market Estimates And Forecast, 2020 - 2032
4.4.2 Dextrose
4.4.2.1 Dextrose Market Estimates And Forecast, 2020 - 2032
4.4.3 Sucrose
4.4.3.1 Sucrose Market Estimates And Forecast, 2020 - 2032
4.4.4 Starch
4.4.4.1 Starch Market Estimates And Forecast, 2020 - 2032
4.4.5 Others
4.4.5.1 Others Market Estimates And Forecast, 2020 - 2032
4.5 Specialty Excipients
4.5.1 Specialty Excipients Market Estimates And Forecast, 2020 - 2032
Chapter 5 Biopharmaceutical Excipients Market: Regional Business Analysis
5.1 Regional Market Snapshot
5.2 North America
5.2.1 North America Biopharmaceutical Excipients Market Estimates And Forecast, 2020 - 2032
5.2.2 U.S.
5.2.2.1 U.S. Biopharmaceutical Excipients Market, 2020 - 2032
5.2.2.2 Key Country Dynamics
5.2.2.3 Regulatory Framework
5.2.2.4 Reimbursement Scenario
5.2.3 Canada
5.2.3.1 Canada Biopharmaceutical Excipients Market, 2020 - 2032
5.2.3.2 Key Country Dynamics
5.2.3.3 Regulatory Framework
5.2.3.4 Reimbursement Scenario
5.3 Europe
5.3.1 Europe Biopharmaceutical Excipients Market, 2020 - 2032
5.3.2 UK
5.3.2.1 UK Biopharmaceutical Excipients Market, 2020 - 2032
5.3.2.2 Key Country Dynamics
5.3.2.3 Regulatory Framework
5.3.2.4 Reimbursement Scenario
5.3.3 Germany
5.3.3.1 Germany Biopharmaceutical Excipients Market, 2020 - 2032
5.3.3.2 Key Country Dynamics
5.3.3.3 Regulatory Framework
5.3.3.4 Reimbursement Scenario
5.3.4 Spain
5.3.4.1 Spain Biopharmaceutical Excipients Market, 2020 - 2032
5.3.4.2 Key Country Dynamics
5.3.4.3 Regulatory Framework
5.3.4.4 Reimbursement Scenario
5.3.5 France
5.3.5.1 France Biopharmaceutical Excipients Market, 2020 - 2032
5.3.5.2 Key Country Dynamics
5.3.5.3 Regulatory Framework
5.3.5.4 Reimbursement Scenario
5.3.6 Italy
5.3.6.1 Italy Biopharmaceutical Excipients Market, 2020 - 2032
5.3.6.2 Key Country Dynamics
5.3.6.3 Regulatory Framework
5.3.6.4 Reimbursement Scenario
5.3.7 Denmark
5.3.7.1 Denmark Biopharmaceutical Excipients Market, 2020 - 2032
5.3.7.2 Key Country Dynamics
5.3.7.3 Regulatory Framework
5.3.7.4 Reimbursement Scenario
5.3.8 Sweden
5.3.8.1 Sweden Biopharmaceutical Excipients Market, 2020 - 2032
5.3.8.2 Key Country Dynamics
5.3.8.3 Regulatory Framework
5.3.8.4 Reimbursement Scenario
5.3.9 Norway
5.3.9.1 Norway Biopharmaceutical Excipients Market, 2020 - 2032
5.3.9.2 Key Country Dynamics
5.3.9.3 Regulatory Framework
5.3.9.4 Reimbursement Scenario
5.4 Asia Pacific
5.4.1 Asia-Pacific Biopharmaceutical Excipients Market, 2020 - 2032
5.4.2 Japan
5.4.2.1 Japan Biopharmaceutical Excipients Market, 2020 - 2032
5.4.2.2 Key Country Dynamics
5.4.2.3 Regulatory Framework
5.4.2.4 Reimbursement Scenario
5.4.3 CHINA
5.4.3.1 China Biopharmaceutical Excipients Market, 2020 - 2032
5.4.3.2 Key Country Dynamics
5.4.3.3 Regulatory Framework
5.4.3.4 Reimbursement Scenario
5.4.4 India
5.4.4.1 India Biopharmaceutical Excipients Market, 2020 - 2032
5.4.4.2 Key Country Dynamics
5.4.4.3 Regulatory Framework
5.4.4.4 Reimbursement Scenario
5.4.5 South Korea
5.4.5.1 South Korea Biopharmaceutical Excipients Market, 2020 - 2032
5.4.5.2 Key Country Dynamics
5.4.5.3 Regulatory Framework
5.4.5.4 Reimbursement Scenario
5.4.6 Thailand
5.4.6.1 Thailand Biopharmaceutical Excipients Market, 2020 - 2032
5.4.6.2 Key Country Dynamics
5.4.6.3 Regulatory Framework
5.4.6.4 Reimbursement Scenario
5.4.7 Australia
5.4.7.1 Australia Biopharmaceutical Excipients Market, 2020 - 2032
5.4.7.2 Key Country Dynamics
5.4.7.3 Regulatory Framework
5.4.7.4 Reimbursement Scenario
5.5 Latin America
5.5.1 Latin America Biopharmaceutical Excipients Market, 2020 - 2032
5.5.2 Brazil
5.5.2.1 Brazil Biopharmaceutical Excipients Market, 2020 - 2032
5.5.2.2 Key Country Dynamics
5.5.2.3 Regulatory Framework
5.5.2.4 Reimbursement Scenario
5.5.3 Mexico
5.5.3.1 Mexico Biopharmaceutical Excipients Market, 2020 - 2032
5.5.3.2 Key Country Dynamics
5.5.3.3 Regulatory Framework
5.5.2.4 Reimbursement Scenario
5.5.4 Argentina
5.5.4.1 Argentina Biopharmaceutical Excipients Market, 2020 - 2032
5.5.4.2 Key Country Dynamics
5.5.4.3 Regulatory Framework
5.5.4.4 Reimbursement Scenario
5.6 MEA
5.6.1 MEA Biopharmaceutical Excipients Market 2020 - 2032
5.6.2 South Africa
5.6.2.1 South Africa Biopharmaceutical Excipients Market, 2020 - 2032
5.6.2.2 Key Country Dynamics
5.6.2.3 Regulatory Framework
5.6.2.4 Reimbursement Scenario
5.6.3 Saudi Arabia
5.6.3.1 Saudi Arabia Biopharmaceutical Excipients Market, 2020 - 2032
5.6.3.2 Key Country Dynamics
5.6.3.3 Regulatory Framework
5.6.3.4 Reimbursement Scenario
5.6.4 UAE
5.6.4.1 UAE Biopharmaceutical Excipients Market, 2020 - 2032
5.6.4.2 Key Country Dynamics
5.6.4.3 Regulatory Framework
5.6.2.4 Reimbursement Scenario
5.6.5 Kuwait
5.6.5.1 Kuwait Biopharmaceutical Excipients Market, 2020 - 2032
5.6.5.2 Key Country Dynamics
5.6.5.3 Regulatory Framework
5.6.5.4 Reimbursement Scenario
Chapter 6 Biopharmaceutical Excipients Market: Competitive Landscape
6.1 Company Categorization
6.2 Strategy Mapping
6.2.1 New product launch
6.2.2 Partnerships
6.2.3 Acquisition
6.2.4 Collaboration
6.2.5 Funding
6.3 Company Market Share Analysis, 2022
6.4 Company Profiles
6.4.1 MERCK KGAA
6.4.1.1 Company overview
6.4.1.2 Financial performance
6.4.1.3 Product benchmarking
6.4.1.4 Strategic initiatives
6.4.2 SIGNET EXCIPIENTS PVT. LTD.
6.4.2.1 Company overview
6.4.2.2 Financial performance
6.4.2.3 Product benchmarking
6.4.2.4 Strategic initiatives
6.4.3 Sigachi Industries Pvt. Ltd
6.4.3.1 Company overview
6.4.3.2 Financial performance
6.4.3.3 Product benchmarking
6.4.3.4 Strategic initiatives
6.4.4 ASSOCIATED BRITISH FOODS
6.4.4.1 Company overview
6.4.4.2 Financial performance
6.4.4.3 Product benchmarking
6.4.4.4 Strategic initiatives
6.4.5 SPECTRUM CHEMICAL MANUFACTURING CORP.
6.4.5.1 Company overview
6.4.5.2 Financial performance
6.4.5.3 Product benchmarking
6.4.5.4 Strategic initiatives
6.4.6 ROQUETTE FRÈRES
6.4.6.1 Company overview
6.4.6.2 Financial performance
6.4.6.3 Product benchmarking
6.4.6.4 Strategic initiatives
6.4.7 DFE PHARMA
6.4.7.1 Company overview
6.4.7.2 Financial performance
6.4.7.3 Product benchmarking
6.4.7.4 Strategic initiatives
6.4.8 CLARIANT
6.4.8.1 Company overview
6.4.8.2 Financial performance
6.4.8.3 Product benchmarking
6.4.8.4 Strategic initiatives
6.4.9 COLORCON
6.4.9.1 Company overview
6.4.9.2 Financial performance
6.4.9.4 Product benchmarking
6.4.9.5 Strategic initiatives
6.4.10 RETTENMAIER & SÖHNE GMBH + CO KG
6.4.10.1 Company overview
6.4.10.2 Financial performance
6.4.10.3 Product benchmarking
6.4.10.4 Strategic initiatives
6.4.11 BASF SE
6.4.11.1 Company overview
6.4.11.2 Financial performance
6.4.11.3 Product benchmarking
6.4.11.4 Strategic initiatives
6.4.12 EVONIK INDUSTRIES AG
6.4.12.1 Company overview
6.4.12.2 Financial performance
6.4.12.3 Product benchmarking
6.4.12.4 Strategic initiatives
6.4.13 IMCD
6.4.12.1 Company overview
6.4.12.2 Financial performance
6.4.12.3 Product benchmarking
6.4.12.4 Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers